Lucy Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Lucy Therapeutics's estimated annual revenue is currently $1.4M per year.
- Lucy Therapeutics's estimated revenue per employee is $77,500
- Lucy Therapeutics's total funding is $6M.
Employee Data
- Lucy Therapeutics has 18 Employees.
- Lucy Therapeutics grew their employee count by 6% last year.
Lucy Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Senior Executive Assistant to the CEO and CSO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Director Pharmacology | Reveal Email/Phone |
4 | Independent Director | Reveal Email/Phone |
5 | Sr. Director, Drug Discovery | Reveal Email/Phone |
6 | Director, Human Resources Strategy | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Senior Director Drug Discovery | Reveal Email/Phone |
10 | Scientist II | Reveal Email/Phone |
Lucy Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Lucy Therapeutics?
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.
keywords:N/A$6M
Total Funding
18
Number of Employees
$1.4M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.1M | 18 | -10% | $161M |
#2 | $3.5M | 18 | N/A | N/A |
#3 | $1.6M | 18 | N/A | N/A |
#4 | $2.5M | 18 | -14% | N/A |
#5 | $3.5M | 18 | -40% | N/A |